Apollomics Inc Cl A (APLM)

$23.00 0.00 (N/A)
Market Cap 25.38M
Revenue (ttm) 1.49M
Net Income (ttm) -53.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,614.77%
Debt to Equity Ratio 0.00
Volume 32,200
Avg Vol 78,312
Day's Range N/A - N/A
Shares Out 1.10M
Stochastic %K 36%
Beta 1.85
Analysts Strong Buy
Price Target $6.50

Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multip...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 209 4055
Fax: 650 288 1674
Address:
989 East Hillsdale Blvd., Suite 220, Foster City, United States
topstockalerts
topstockalerts Oct. 25 at 1:37 PM
After Hours Top Gainers PT2 $ASST $DMAA $APLM $DMAAU $CUPR
3 · Reply
Dr24stock
Dr24stock Oct. 24 at 7:36 PM
$APLM oh yeah Baby, keep going...
0 · Reply
Dr24stock
Dr24stock Oct. 20 at 10:24 AM
$APLM nice moment when that turned out to be true. Meanwhile, volume of 500 on the day.
1 · Reply
Indexing4
Indexing4 Oct. 20 at 10:17 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH ✅🔥 Consistent growth, solid volume, strong communities Add to watchlist and stay ready
0 · Reply
Indexing4
Indexing4 Oct. 20 at 10:17 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Indexing4
Indexing4 Oct. 20 at 10:17 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Indexing4
Indexing4 Oct. 20 at 10:17 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Nosi69420
Nosi69420 Oct. 20 at 10:16 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Nosi69420
Nosi69420 Oct. 20 at 10:16 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Nosi69420
Nosi69420 Oct. 20 at 10:16 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Latest News on APLM
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Oct 15, 2025, 2:36 PM EDT - 12 days ago

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Apollomics, Inc. Company Operational Continuity Update

Oct 13, 2025, 9:22 PM EDT - 13 days ago

Apollomics, Inc. Company Operational Continuity Update

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apr 3, 2025, 4:05 PM EDT - 7 months ago

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Mar 31, 2025, 8:00 AM EDT - 7 months ago

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 20, 2024, 8:00 AM EST - 11 months ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 10, 2024, 4:05 PM EST - 11 months ago

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 14, 2024, 6:00 AM EDT - 1 year ago

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Jul 16, 2024, 4:47 PM EDT - 1 year ago

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 3:57 PM EDT - 1 year ago

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Mar 4, 2024, 7:00 AM EST - 1 year ago

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 7:00 AM EST - 1 year ago

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 19, 2024, 4:15 PM EST - 1 year ago

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Jan 17, 2024, 4:30 PM EST - 1 year ago

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jan 3, 2024, 7:00 AM EST - 1 year ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics to Present at the 2024 Biotech Showcase

Jan 2, 2024, 4:30 PM EST - 1 year ago

Apollomics to Present at the 2024 Biotech Showcase

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 29, 2023, 7:30 AM EST - 2 years ago

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Nov 28, 2023, 7:00 AM EST - 2 years ago

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Nov 16, 2023, 8:30 AM EST - 2 years ago

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Oct 26, 2023, 8:50 AM EDT - 2 years ago

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Oct 23, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Oct 16, 2023, 6:55 PM EDT - 2 years ago

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Sep 28, 2023, 4:17 PM EDT - 2 years ago

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Aug 29, 2023, 6:21 AM EDT - 2 years ago

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

Apr 26, 2023, 7:45 AM EDT - 2 years ago

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

ANGO

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Jan 13, 2023, 4:13 PM EST - 3 years ago

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Oct 7, 2022, 4:05 PM EDT - 3 years ago

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

topstockalerts
topstockalerts Oct. 25 at 1:37 PM
After Hours Top Gainers PT2 $ASST $DMAA $APLM $DMAAU $CUPR
3 · Reply
Dr24stock
Dr24stock Oct. 24 at 7:36 PM
$APLM oh yeah Baby, keep going...
0 · Reply
Dr24stock
Dr24stock Oct. 20 at 10:24 AM
$APLM nice moment when that turned out to be true. Meanwhile, volume of 500 on the day.
1 · Reply
Indexing4
Indexing4 Oct. 20 at 10:17 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH ✅🔥 Consistent growth, solid volume, strong communities Add to watchlist and stay ready
0 · Reply
Indexing4
Indexing4 Oct. 20 at 10:17 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Indexing4
Indexing4 Oct. 20 at 10:17 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Indexing4
Indexing4 Oct. 20 at 10:17 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Nosi69420
Nosi69420 Oct. 20 at 10:16 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Nosi69420
Nosi69420 Oct. 20 at 10:16 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Nosi69420
Nosi69420 Oct. 20 at 10:16 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Nosi69420
Nosi69420 Oct. 20 at 10:16 AM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
Dr24stock
Dr24stock Oct. 20 at 9:46 AM
$APLM wen offering?
0 · Reply
xfuelx
xfuelx Oct. 19 at 6:38 PM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
xfuelx
xfuelx Oct. 19 at 6:38 PM
$APLM $BMNR $BOND.X $WAGMI.X $XCH
0 · Reply
passthedutcher
passthedutcher Oct. 19 at 6:33 PM
$APLM $BMNR $BOND.X $WAGMI.X $XCH 👀👀
0 · Reply
Whiskey1679
Whiskey1679 Oct. 19 at 6:32 PM
Whiskey's Penny Picks out tomorrow. I'll have 1 Pick Post approx. 6:15 am PDT. The other just after the 6:30 am bell PDT! Trending a bit & some of Friday's Gainers: $XCH $BOND.X $APLM $WAGMI.X $BMNR
0 · Reply
Maximum_Gains
Maximum_Gains Oct. 19 at 6:01 PM
$OMEX $MNMD $APLM $IMDX VRME last time this had this much buzz it ran to $5+ with 200M volume! Now with compliance news and upcoming Crypto strategy PR, this could ones again can go big. Don't miss VRME bulls!
0 · Reply
PaulLaurent
PaulLaurent Oct. 19 at 5:23 PM
🚀📈 Top Gainers 📈🚀 Last Week $APLM $STI $RANI $PRAX $COOT
0 · Reply
SpartanVI
SpartanVI Oct. 18 at 3:19 PM
$SUGP $SPRB $WOLF $NUAI $APLM Crazy Undervalued Ticker Very small float too Monday potential 🔥👇
1 · Reply
Paraboljoker
Paraboljoker Oct. 18 at 3:14 PM
$SUGP SUGP is trending as traders discuss its low float and potential for a short squeeze, drawing comparisons to other Hong Kong-based stocks that have recently seen significant gains. Community members are pointing to the company's regained NASDAQ compliance and a substantial contract that exceeds its market capitalization as potential catalysts. The high cost to borrow is also fueling speculation about a potential squeeze like $SPRB $WOLF $NUAI $APLM
0 · Reply
aspen5
aspen5 Oct. 17 at 5:02 PM
$APLM I like it how this stock pumps up everyday with no news and no volume. I usually make a $2 profit which is great.
0 · Reply
makedatbread88
makedatbread88 Oct. 17 at 4:45 PM
$APLM now 800% my lord… ***Follow me for more winning calls!***
1 · Reply